Cytokinetics director receives stock and option grants

Cytokinetics Inc. director Wendell Wierenga reported equity compensation awards.

Rhea-AI Filing Summary

Cytokinetics Inc. director Wendell Wierenga reported equity compensation awards. On May 27, 2026, he received 2,851 shares of Common Stock as a grant at no cash cost, increasing his direct holdings to 35,488 shares.

He was also granted a Non-Qualified Stock Option for 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option is scheduled to become exercisable starting June 27, 2026 and expires on May 26, 2036, adding to his long-term incentive position with the company.

Insider Trade Summary

Grant/Award: 7,152 shares

Grant/Award 2 txns

Insider WIERENGA WENDELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (Right to Buy)	4,301	$0.00	$0.00
Grant/Award	Common Stock	2,851	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 4,301 contracts (Direct); Common Stock — 35,488 shares (Direct)

Key Figures

Common stock grant: 2,851 shares Option grant shares: 4,301 shares Option exercise price: $77.15 per share +3 more

6 metrics

Common stock grant 2,851 shares Equity award on May 27, 2026

Option grant shares 4,301 shares Non-Qualified Stock Option awarded May 27, 2026

Option exercise price $77.15 per share Non-Qualified Stock Option for 4,301 shares

Shares owned after grant 35,488 shares Director’s direct Common Stock holdings after award

Option expiration date May 26, 2036 Non-Qualified Stock Option term end

Option exercisable date June 27, 2026 Earliest exercise date for 4,301-share option

Key Terms

Non-Qualified Stock Option (Right to Buy), Common Stock, grant/award acquisition, Form 4

4 terms

Non-Qualified Stock Option (Right to Buy) financial

"Security title listed as "Non-Qualified Stock Option (Right to Buy)""

Common Stock financial

"Security title for the 2,851-share grant is "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant/award acquisition financial

"transaction_action field describes the event as "grant/award acquisition""

Form 4 regulatory

"Insider transaction data is reported in a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTOKINETICS (CYTK) disclose for Wendell Wierenga?

Cytokinetics reported that director Wendell Wierenga received equity compensation. He was granted 2,851 shares of Common Stock and a stock option for 4,301 shares, both recorded on May 27, 2026 as direct ownership awards.

How many CYTOKINETICS (CYTK) shares does Wendell Wierenga hold after this Form 4?

After the May 27, 2026 grant, Wendell Wierenga directly owns 35,488 shares of Cytokinetics Common Stock. This figure reflects the newly awarded 2,851-share grant added to his prior holdings, as reported in the Form 4 filing.

What are the key terms of Wendell Wierenga’s new CYTOKINETICS (CYTK) stock option?

Wendell Wierenga received a Non-Qualified Stock Option covering 4,301 shares of Cytokinetics Common Stock at an exercise price of $77.15 per share. The option becomes exercisable starting June 27, 2026 and expires on May 26, 2036.

Is the CYTOKINETICS (CYTK) Form 4 transaction a purchase or a grant?

The Form 4 shows grant or award acquisitions rather than open-market purchases. Both the 2,851-share Common Stock award and the 4,301-share stock option were reported with code A, indicating compensation-related grants at no cash purchase price.

Does the CYTOKINETICS (CYTK) filing show any insider stock sales?

The disclosed Form 4 for Wendell Wierenga does not report any stock sales. It lists two acquisition transactions, both coded as grants or awards: one in Common Stock and one in a Non-Qualified Stock Option, with no dispositions reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIERENGA WENDELL

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		A		2,851	A	$0	35,488	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$77.15	05/27/2026		A		4,301		06/27/2026	05/26/2036	Common Stock	4,301	$0	4,301	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)